Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Infect Dis ; 24(1): 615, 2024 Jun 21.
Article in English | MEDLINE | ID: mdl-38907220

ABSTRACT

OBJECTIVE: To determine the relationship of Neutrophil Lymphocyte Ratio (NLR), Monocyte Lymphocyte Ratio (MLR), and Neutrophil Monocyte Ratio (NMR) with treatment response in Pulmonary Tuberculosis (PTB) patients during intensive phase treatment (IPT). METHODS: This analytical cross-sectional study was conducted at Ojha Institute of Chest Diseases (OICD), Dow University of Health Sciences, from February to December 2021. 100 patients were enrolled using purposive sampling technique. Both male and female of age 18 and above, rifampicin sensitive newly diagnosed cases of PTB by Acid Fast Bacilli (AFB) microscopy and Gene Xpert MTB/RIF were included. SPSS version 26 was used to analyze data. Numerical data was expressed in median and interquartile range and categorical data was expressed in frequencies and percentages. RESULTS: Out of total 100 patients, 81% (n = 81) showed treatment response with negative AFB Sputum Smear Microscopy (SSM) after 2nd month. Out of 81% (n = 81) of the patients who achieved treatment response, 83.9% (n = 68) also had decreased NLR, 85.2% (n = 69) had decreased MLR and 83.9% (n = 68) had decreased NMR from baseline. However 19% (n = 19) did not achieved treatment response with positive AFB SSM after 2nd month of ATT (Anti tuberculosis treatment), among them 10.52% (n = 2) were INH resistant with no decrease in all the ratios after 2nd month. CONCLUSION: Leukocyte ratios decreased significantly from baseline as PTB was treated in patients who achieved treatment response with negative AFB SSM after two months of ATT and hence these ratios could be used as markers to monitor the treatment response.


Subject(s)
Antitubercular Agents , Lymphocytes , Monocytes , Neutrophils , Tuberculosis, Pulmonary , Humans , Male , Female , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/blood , Tuberculosis, Pulmonary/microbiology , Adult , Cross-Sectional Studies , Middle Aged , Antitubercular Agents/therapeutic use , Treatment Outcome , Young Adult , Sputum/microbiology , Adolescent , Rifampin/therapeutic use
2.
Food Sci Biotechnol ; 25(4): 1095-1100, 2016.
Article in English | MEDLINE | ID: mdl-30263380

ABSTRACT

This study evaluates the antioxidant, antimicrobial, and antiproliferative activities of mushroom varieties (Agaricus bisporus, Pleurotus ostreatus, and Coprinus atramentarius) found in the Himalayan regions of Jammu and Kashmir, India. All three mushroom varieties exhibited antioxidant activity. A. bisporus showed the highest diphenyl-2-picrylhydrazyl inhibition activity (87.88±5.6%), C. atramentarius showed the highest reducing power (0.49±0.01) and metal chelating ability (48.57± 0.38%), and P. ostreatus contained the highest phenolic (5.25±0.14 mg gallic acid equivalent per gram) and flavonoid content (64.39±0.73 µg rutin equivalent per gram). C. atramentarius showed maximum antibacterial activity against all the pathogenic strains and the highest zone of inhibition was against S. typhi (7.45±0.5 mm). P. ostreatus exhibited the highest cell proliferation inhibition against Colo-205 and MCF-7 cancer cell lines. The structural analysis by Fourier transform infrared spectroscopy indicated the presence of ß-configuration in carbohydrates, phenolic compounds, and protein, which impart nutraceutical properties to mushrooms.

SELECTION OF CITATIONS
SEARCH DETAIL